Article
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
The Journal of antimicrobial chemotherapy - 1 May 2019
Nyaku Amesika N, Zheng Lu, Gulick Roy M, Olefsky Maxine, Berzins Baiba, Wallis Carole L, Godfrey Catherine, Sax Paul E, Acosta Edward P, Haas David W, Smith Kimberly Y, Sha Beverly E, Van Dam Cornelius N, Taiwo Babafemi O
Abstract excerpt
BACKGROUND: The AIDS Clinical Trials Group study A5353 demonstrated the efficacy and safety of dolutegravir and lamivudine for initial treatment of HIV-1 infection at week 24 in individuals with HIV-1 RNA 1000-500 000 copies/mL. Optimal ART for treatment-naive individuals must be durable. OBJECTIVES: The aim of this study was to estimate the efficacy and safety of dolutegravir plus lamivudine at week 48 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.